Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire May 29, 2024

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

GlobeNewswire May 9, 2024

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

GlobeNewswire May 8, 2024

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

GlobeNewswire May 1, 2024

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

GlobeNewswire April 23, 2024

Tarsus to Participate at Upcoming Investor Conferences

GlobeNewswire March 5, 2024

Tarsus Introduces "Mite Party" Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

GlobeNewswire March 5, 2024

Tarsus Announces Pricing of $100.0 Million Public Offering

GlobeNewswire March 1, 2024

Tarsus Announces Proposed $100.0 Million Public Offering

GlobeNewswire February 29, 2024

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

GlobeNewswire February 27, 2024

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

GlobeNewswire February 22, 2024

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

GlobeNewswire February 20, 2024

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

GlobeNewswire January 31, 2024

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

GlobeNewswire December 11, 2023

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

GlobeNewswire November 9, 2023

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

GlobeNewswire November 1, 2023

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY(TM), the First and Only FDA Approved Treatment for Demodex Blepharitis

GlobeNewswire September 6, 2023

Tarsus to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2023

Now Available - XDEMVY(TM) (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

GlobeNewswire August 24, 2023

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

GlobeNewswire August 10, 2023